Video content above is prompted by the following: McMichael: How do you see treatment algorithms changing with the introduction of JAK inhibitor therapies? How do you think payers should anticipate covering AA in the next few years? Friedland: What do […]
Future Treatment of Patients With Alopecia Areata Read More »
Video content above is prompted by the following: Thanks to all of you for this rich and informative discussion. Before we conclude I’d like to get final thoughts from each of you. Source link Ryan Haumschild, PharmD, MS, MBA
Final Takeaways From the Panelists Read More »
Video content above is prompted by the following: Ungar: The Severity of Alopecia Tool (SALT) is a validated tool utilized to assess the clinical severity of alopecia with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp
Rapid Therapeutic Effects Seen With a JAK Inhibitor Read More »
Video content above is prompted by the following: Ungar: The Severity of Alopecia Tool (SALT) is a validated tool utilized to assess the clinical severity of alopecia with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp
SALT Scoring for Alopecia Areata Read More »
Video content above is prompted by the following: McMichael: What are the hallmark symptoms of AA, and how can it fluctuate with time making this a relapsing or remitting inflammatory disease? Source link Ryan Haumschild, PharmD, MS, MBA
Hallmark Symptoms Seen With Alopecia Areata Read More »
Video content above is prompted by the following: Friedland: In addition to dermatologic symptoms, there are also psychological effects seen from ongoing or recurrent hair loss. How can may this these impact the mental health of the patient? Friedland: Are
Psychosocial Impact of Alopecia Areata Read More »
Video content above is prompted by the following: Ungar: What is the epidemiology of AA, and can you describe the different forms of AA that you see in your practice? Is there a population in which AA occurs more frequently
Epidemiology Associated With Alopecia Areata Read More »
Video content above is prompted by the following: Mostaghimi: What are the concurrent comorbidities commonly seen in patients with AA? How do they contribute to the burden of disease? How do these affect your management plan? Source link Ryan Haumschild,
Common Comorbidities Associated With Alopecia Areata Read More »
Video content above is prompted by the following: Describe the pathophysiology of alopecia areata (AA) and what makes it a chronic, autoimmune disease?. a. Describe the role of inflammation in AA. Source link Ryan Haumschild, PharmD, MS, MBA
Discussing the Pathophysiology of Alopecia Areata Read More »
We’ve discussed first-line therapies and a newly approved therapy tarlatamab. Beyond first-line therapies, what options exist for patients, and what clinical trials are you excited about? What are some of the therapies being researched for small cell lung cancer (SCLC)
Key Takeaways on Recent Advances in SCLC Read More »
